Compare SLQT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLQT | CGTX |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 79.6M |
| IPO Year | 2020 | 2021 |
| Metric | SLQT | CGTX |
|---|---|---|
| Price | $0.37 | $0.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.13 | ★ $3.33 |
| AVG Volume (30 Days) | ★ 931.4K | 400.1K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,618,499,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 6.02 | N/A |
| 52 Week Low | $0.38 | $0.55 |
| 52 Week High | $2.22 | $2.05 |
| Indicator | SLQT | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.10 | 43.33 |
| Support Level | N/A | $0.91 |
| Resistance Level | $0.79 | $1.18 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 7.58 | 24.53 |
SelectQuote Inc is a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. Its insurance distribution business allows consumers to transparently and conveniently shop for senior health, life, and automobile and home insurance policies from a curated panel of the nation's insurance carriers. It operates in three reportable segments: Senior, Healthcare Services, and Life. Senior sells senior Medicare-related health insurance products. Healthcare Services includes SelectRx, Healthcare Select, and SPM. Healthcare Services provides products and services to its Medicare policyholders, which are focused on improving patient health outcomes. Life sells term life and final expense products.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).